Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-n

Effect: improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29